Predictors and impact of timing of disease progression following primary therapy in multiple myeloma

We examined the outcomes of 1557 MM patients stratified into short (5 years) PFS. Short PFS occurred in 758 patients (48.7%), medium in 561 patients (36.2%), and long in 238 patients (15.3%). Median post-progression PFS was 9.2 months (95% CI 8.1-11.0) in the short PFS and 33.1 months (95% CI 29.0-42.1; p

Source: Clinical Lymphoma, Myeloma and Leukemia - November 27, 2023 Category: Hematology Authors: Sarah Goldman-Mazur, Alissa Visram, S. Vincent Rajkumar, Prashant Kapoor, Angela Dispenzieri, Martha Q. Lacy, Morie A. Gertz, Francis K. Buadi, Suzanne R. Hayman, David Dingli, Taxiarchis Kourelis, Wilson Gonsalves, Rahma Warsame, Eli Muchtar, Nelson Leun Tags: Original Study Source Type: research